At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RNXT RenovoRx Inc
Market Closed 02-27 16:00:00 EST
0.8830
+0.0180
+2.08%
盘后0.8807
-0.0023-0.26%
19:50 EST
High0.9380Low0.8651Vol510.10K
Open0.9200D1 Closing0.8650Amplitude8.43%
Mkt Cap32.36MTradable Cap26.57MTotal Shares36.65M
T/O463.82KT/O Rate1.70%Tradable Shares30.09M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

RenovoRx Names Ramtin Agah Executive Chairman
Reuters  ·  02-27 21:30
RenovoRx Names Ramtin Agah Executive Chairman
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum
GlobeNewswire  ·  02-27 21:30
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum
RenovoRx to Present TAMP Therapy Platform Pancreatic Cancer PET/CT Findings at 2026 Society of Interventional Radiology Annual Scientific Meeting
Reuters  ·  02-26 21:31
RenovoRx to Present TAMP Therapy Platform Pancreatic Cancer PET/CT Findings at 2026 Society of Interventional Radiology Annual Scientific Meeting
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and RenovoRx (RNXT)
TIPRANKS  ·  02-18
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and RenovoRx (RNXT)
RenovoRx Is Maintained at Buy by Ascendiant Capital
Dow Jones  ·  02-17
RenovoRx Is Maintained at Buy by Ascendiant Capital
BRIEF-Renovorx Formation Of Renovocath Medical Advisory Board To Support Clinical And Strategic Initiatives
Reuters  ·  02-10
BRIEF-Renovorx Formation Of Renovocath Medical Advisory Board To Support Clinical And Strategic Initiatives
RenovoRx - Formation of Renovocath Medical Advisory Board to Support Clinical and Strategic Initiatives
THOMSON REUTERS  ·  02-10
RenovoRx - Formation of Renovocath Medical Advisory Board to Support Clinical and Strategic Initiatives
Press Release: RenovoRx Establishes RenovoCath(R) Medical Advisory Board
Dow Jones  ·  02-10
Press Release: RenovoRx Establishes RenovoCath(R) Medical Advisory Board
RenovoRx appoints Voll as Chief Financial Officer
TIPRANKS  ·  02-05
RenovoRx appoints Voll as Chief Financial Officer
RenovoRx Names Mark Voll Chief Financial Officer
Reuters  ·  02-05
RenovoRx Names Mark Voll Chief Financial Officer
Press Release: RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer
Dow Jones  ·  02-05
Press Release: RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer
RenovoRx Unveils Clinical Data Supporting TAMP Therapy Platform at SIO 2026 Meeting
Reuters  ·  02-04
RenovoRx Unveils Clinical Data Supporting TAMP Therapy Platform at SIO 2026 Meeting
RenovoRx Announces Clinical Data Supporting the Tamp™ Therapy Platform Will Be Presented at the Sio 2026 Annual Scientific Meeting
THOMSON REUTERS  ·  02-04
RenovoRx Announces Clinical Data Supporting the Tamp™ Therapy Platform Will Be Presented at the Sio 2026 Annual Scientific Meeting
RenovoRx Inc. details RenovoCath commercialization progress and pipeline developments in new investor presentation
Reuters  ·  02-03
RenovoRx Inc. details RenovoCath commercialization progress and pipeline developments in new investor presentation
RenovoRx Reports $900,000 in RenovoCath Sales for First Nine Months of 2025
Reuters  ·  01-28
RenovoRx Reports $900,000 in RenovoCath Sales for First Nine Months of 2025
RenovoRx to Present New Clinical Data on Pressure-Guided Chemotherapy Delivery at SIO 2026 Meeting
Reuters  ·  01-28
RenovoRx to Present New Clinical Data on Pressure-Guided Chemotherapy Delivery at SIO 2026 Meeting
RenovoRx Chief Medical Officer Ramtin Agah Reports Acquisition of Common Shares
Reuters  ·  01-22
RenovoRx Chief Medical Officer Ramtin Agah Reports Acquisition of Common Shares
RenovoRx Inc. unveils investor presentation highlighting RenovoCath commercialization and clinical progress
Reuters  ·  01-20
RenovoRx Inc. unveils investor presentation highlighting RenovoCath commercialization and clinical progress
RenovoRx CEO to Present at AlphaNorth Capital Event
Reuters  ·  01-14
RenovoRx CEO to Present at AlphaNorth Capital Event
RenovoRx Unveils Promising Phase III Data on TAMP Platform for Pancreatic Cancer at ASCO GI 2026
Reuters  ·  01-08
RenovoRx Unveils Promising Phase III Data on TAMP Platform for Pancreatic Cancer at ASCO GI 2026

Introduction

Company Name.
RenovoRx Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
Issue price:
--